What does this company do and how does it make money?

IDEXX dominates veterinary diagnostics through an integrated platform of instruments, consumables, and lab services that creates switching costs for veterinary practices. The 96.9% correlation with inflation demonstrates exceptional pricing power, while high customer retention in diagnostic services provides predictable recurring revenue.

Five legendary investment frameworks analyzed this company.

Warren Buffett's framework rates IDEXX at just 0.65 despite its billion-dollar cash flow, while institutional ownership crossed 100% for the first time as insiders dumped $17.6 million in shares. Tap any framework below to explore their complete analysis and discover why positions range from Howard Marks' cautious 0.20 to Buffett's measured optimism.

How much cash does it generate and where does it go?

IDEXX generates over a billion in free cash flow annually, but allocates two-thirds to buybacks that are now underwater at $591.54 average price versus $569.55 current. The capital-light model requires minimal capex while R&D investment sustains the innovation pipeline, though aggressive buybacks have left returns trailing the 11.83% cost of capital.

Is the business getting stronger or weaker?

While IDEXX maintains strong absolute margins and EPS near decade highs, the negative operating leverage reveals vulnerability when growth slows. The 239 basis point gap between ROIC and WACC indicates the business is destroying value at current capital deployment levels despite robust cash generation.

What could go wrong and has it survived trouble before?

IDEXX demonstrated resilience during COVID with rapid FCF recovery, but current risks center on ownership dynamics where institutions own over 100% while insiders consistently sell. The high concentration in both Product segment and U.S. geography creates vulnerability to disruption or regulatory changes.

When institutions own 100.6% of your company but insiders are net sellers in 14 of 20 quarters, someone is wrong about the future.

Is the stock priced for perfection, fair value, or pessimism?

IDEXX trades at extreme valuations requiring near-double-digit perpetual growth to justify a 0.46% earnings yield in a 4.33% risk-free world. With the stock 245% above DCF fair value and minimal reaction to earnings beats, the market has already priced in exceptional execution.